Use of buckysome or carbon nanotube for drug delivery
First Claim
Patent Images
1. A vesicle having an interior, an exterior, and a wall, wherein the wall comprises one or more layers, wherein each layer comprises a substituted fullerene having structure I:
-
(B)b—
Cn-(A)a
(I)wherein Cn is a fullerene moiety comprising n carbon atoms, wherein n is an integer and 60≦
n≦
240;
B is an organic moiety comprising from 1 to about 40 polar headgroup moieties;
b is an integer and 1≦
b≦
5;
each B is covalently bonded to the Cn through 1 or 2 carbon-carbon, carbon-oxygen, or carbon-nitrogen bonds;
A is an organic moiety comprising a terminus proximal to the Cn and one or more termini distal to the Cn, wherein the termini distal to the Cn each comprise —
CxHy, wherein x is an integer and 8≦
x≦
24, and y is an integer and 1≦
y≦
2x+1;
a is an integer, 1≦
a≦
5;
2≦
b+a≦
6; and
each A is covalently bonded to the Cn through 1 or 2 carbon-carbon, carbon-oxygen, or carbon-nitrogen bonds,wherein the vesicle wall comprises at least about 50 mol % the substituted fullerene; and
,wherein the interior of the vesicle, a portion of the wall between two layers, or both comprise a therapeutic agent.
7 Assignments
0 Petitions
Accused Products
Abstract
Compositions and methods for administering a therapeutic agent to a mammal are disclosed. The compositions comprise either (i) vesicles comprising an amphiphilic substituted fullerene, wherein the therapeutic agent is present in the vesicle interior or between layers of the vesicle wall, (ii) a substituted fullerene, comprising a fullerene core and a functional moiety, wherein the therapeutic agent is associated with the substituted fullerene, or (iii) carbon nanotubes, wherein the therapeutic agent is covalently bonded to the carbon nanotubes.
-
Citations
25 Claims
-
1. A vesicle having an interior, an exterior, and a wall, wherein the wall comprises one or more layers, wherein each layer comprises a substituted fullerene having structure I:
-
(B)b—
Cn-(A)a
(I)wherein Cn is a fullerene moiety comprising n carbon atoms, wherein n is an integer and 60≦
n≦
240;B is an organic moiety comprising from 1 to about 40 polar headgroup moieties; b is an integer and 1≦
b≦
5;each B is covalently bonded to the Cn through 1 or 2 carbon-carbon, carbon-oxygen, or carbon-nitrogen bonds; A is an organic moiety comprising a terminus proximal to the Cn and one or more termini distal to the Cn, wherein the termini distal to the Cn each comprise —
CxHy, wherein x is an integer and 8≦
x≦
24, and y is an integer and 1≦
y≦
2x+1;a is an integer, 1≦
a≦
5;2≦
b+a≦
6; andeach A is covalently bonded to the Cn through 1 or 2 carbon-carbon, carbon-oxygen, or carbon-nitrogen bonds, wherein the vesicle wall comprises at least about 50 mol % the substituted fullerene; and
,wherein the interior of the vesicle, a portion of the wall between two layers, or both comprise a therapeutic agent. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11)
-
-
12. A method of administering a therapeutic agent to a mammal, comprising:
-
(i) administering a solution comprising a pharmaceutically effective amount of the therapeutic agent, wherein the therapeutic agent is present in (a) the interior of a vesicle having an interior, an exterior, and a wall, (b) a portion of the wall between two layers, or (c) both, to the mammal, wherein the wall comprises one or more layers, wherein each layer comprises a substituted fullerene having structure I;
(B)b—
Cn-(A)a
(I)wherein Cn is a fullerene moiety comprising n carbon atoms, wherein n is an integer and 60≦
n≦
240;B is an organic moiety comprising from 1 to about 40 polar headgroup moieties; b is an integer and 1≦
b≦
5;each B is covalently bonded to the Cn through 1 or 2 carbon-carbon, carbon-oxygen, or carbon-nitrogen bonds; A is an organic moiety comprising a terminus proximal to the Cn and one or more termini distal to the Cn, wherein the termini distal to the Cn each comprise —
CxHy, wherein x is an integer and 8≦
x≦
24, and y is an integer and 1≦
y≦
2x+1;a is an integer, 1≦
a≦
5;2≦
b+a≦
6; andeach A is covalently bonded to the Cn through 1 or 2 carbon-carbon, carbon-oxygen, or carbon-nitrogen bonds, wherein the vesicle wall comprises at least about 50 mol % the substituted fullerene. - View Dependent Claims (13, 14, 15, 16, 17, 18, 19, 20)
-
-
21. A method of reversibly forming a vesicle having an interior, an exterior, and a wall, wherein the wall comprises one or more layers and the interior of the vesicle, a portion of the wall between two layers, or both comprise a therapeutic agent, comprising:
-
dissolving in an aqueous solvent (a) a substituted fullerene having the structure I;
(B)b—
Cn-(A)a
(I)wherein Cn is a fullerene moiety comprising n carbon atoms, wherein n is an integer and 60≦
n≦
240;B is an organic moiety comprising from 1 to about 40 polar headgroup moieties; b is an integer and 1≦
b≦
5;each B is covalently bonded to the Cn through 1 or 2 carbon-carbon, carbon-oxygen, or carbon-nitrogen bonds; A is an organic moiety comprising a terminus proximal to the Cn and one or more termini distal to the Cn, wherein the termini distal to the Cn each comprise —
CxHy, wherein x is an integer and 8≦
x≦
24, and y is an integer and 1≦
y≦
2x+1;a is an integer, 1≦
a≦
5;2≦
b+a≦
6; andeach A is covalently bonded to the Cn through 1 or 2 carbon-carbon, carbon-oxygen, or carbon-nitrogen bonds, and (b) the therapeutic agent, wherein the pH of the solvent is sufficiently low to form a vesicle from the substituted fullerene and the vesicle comprise at least 50 mole % of the fullerene. - View Dependent Claims (22, 23, 24, 25)
-
Specification